Up-to-date Information on
Waldenström’s macroglobulinemia



The state-of-the-art glossary for Waldenström’s macroglobulinemia.


MYD88 in the glossary for Waldenström's macroglobulinemia

MYD88 (myeloid differentiation factor 88) is a driver gene found in hematologic B-cell malignancies.

MyD88 is the adaptor for inflammatory signaling pathways downstream of members of the Toll-like receptor (TLR) and interleukin-1 (IL1) receptor families. MyD88 links IL1R or TLR family members to IL-1R-associated kinase (IRAK) family proteins. Activation of IRAK family proteins leads to the activation of nuclear factor-kappa B (NFkB), mitogen-activated protein kinases (MAPK), and activator protein 1 (AP1), making MyD88 a central mediator of inflammatory pathways. MYD88 mutations are a driver in hematologic B-cell malignancies. The missense mutation L265P is found in over 90% of Waldenström’s macroglobulinemia cases.1,2

Glossary overview


1.Deguine J and Barton GM. MyD88: a central player in innate immune signaling. F1000Prime Rep 2014: 6;97.
2.Divoka M, Pika T, Krupkova L, et al. Clinical Implications of MYD88 and CXCR4 in Patients with Waldenströms Macroglobulinemia Blood. 2018: 132 (Supplement 1);5314.
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.